Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Completes Sale of TachoSil® to Corza Health
February 1, 2021 GMT
OSAKA, Japan (BUSINESS WIRE) Feb 1, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil ® Fibrin Sealant Patch (“TachoSil ® ”) to Corza Health, Inc. (“Corza”) for €350 million.
ADVERTISEMENT
TachoSil ® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil®, while Takeda maintains ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing & supply agreement, under which it will continue to exclusively manufacture TachoSil
Takeda Pharmaceutical Company Limited: Takeda schließt Verkauf von ausgewählten rezeptfreien und nicht zum Kerngeschäft gehörenden Aktiva an Hypera Pharma ab finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dec 21, 2020 07:00 UTC
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD OSAKA, Japan (Business Wire) Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. (China) (“Hasten”), a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited (“Ray Capital”)
1 Takeda will receive $322 million USD, subject to customary legal and regulatory closing conditions.
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China. The portfolio generated FY2019 net sales of approximately $109.5 million USD, driven by strong sales of cardiovascular products such as Ebrantil